Skip to main

Impact case study database

The impact case study database allows you to browse and search for impact case studies submitted to the REF 2021. Use the search and filters below to find the impact case studies you are looking for.
Impact case study database FAQs
Download all impact case studies (spreadsheet)
Download all impact case studies (spreadsheet) (generating)
Back

Identifying BRAF as a key target for the development of novel cancer therapeutics

Download case study PDF
Submitting institution
Institute of Cancer Research: Royal Cancer Hospital (The)
Unit of assessment
5 - Biological Sciences
Summary impact type
Technological
Request cross-referral to
-
Is this case study continued from a case study submitted in 2014?
Yes

1. Summary of the impact

2. Underpinning research

3. References to the research

4. Details of the impact

5. Sources to corroborate the impact

Additional contextual information

Grant funding

Grant number Value of grant
C5759/A3995 £170,603
C5759/A5714 £47,883
C1364/A6473 £110,992
C107/A10433 £13,255,685
071487/Z/03/A £50,201
080333/Z/06/Z £2,292,192
C309/A8274 £29,156,418
09-0773 £196,852
CTR-Q3-Y1 £5,900,000
CTR-Q3-Y2 £23,200,000
INT - HER 07/08 £192,094
GF011 £392,147
C107/A3955 £1,496,294
C107/A18577 £193,757
096444/Z/11/Z £3,004,236
None given £10,000
A17240 £0
BRC-2011-10059 £61,543,735
651 CL-2008-22-001 £7,004
C309/A11566 £40,964,687
Countries
  • US
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • Iceland
  • Liechtenstein
  • Norway
  • UK
  • Japan
  • Australia
  • Canada
  • Switzerland
Formal partners
  • The Wellcome Trust Sanger Institute
  • University of Manchester
  • The Wellcome Trust
Funding programmes
  • Cancer Research UK: Inhibitors of Activated BRAF
  • Cancer Research UK: Inhibitors of BRAF
  • Cancer Research UK: Inhibitors of Oncogenic BRAF
  • Cancer Research UK: Cell and Molecular Biology - Tumour Cell Signalling Networks
  • Wellcome Trust: Inhibitors of BRAF
  • Wellcome Trust: Development of 2 Series of Systemic/Oral Inhibitor
  • Cancer Research UK: Cancer Therapeutics Unit (CTU) grant (2006 to 2011)
  • Worldwide Cancer Research: AMPK signalling in melanoma: biology and therapeutic opportunities
  • Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2010 to 2011
  • Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2011 to 2015
  • Breast Cancer Now (previously Breakthrough Breast Cancer): Identification and functional validation of additional therapeutic targets in HER2 amplified breast cancers
  • Cancer Research UK: Marshall Gibb Fellowship (1998)
  • Cancer Research UK: Marshall Gibb Fellowship (2002)
  • Cancer Research UK: Marshall Gibb Fellowship (2014)
  • Wellcome Trust: Preclinical and Clinical Development BRAF Inhibitors
  • Cancer Research UK: 2010 Future Leaders Prize in Cancer Research
  • Cancer Research UK: Molecular Oncology Group funding
  • The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2012)
  • National Institute of Health Research: Academic Clinical Lecturer (ACL)
  • Cancer Research UK: Cancer Therapeutics Unit (CTU) grant (2011 to 2017)
Global research identifiers
  • grid.11485.39
  • grid.52788.30
  • grid.453093.8
  • grid.458394.7
  • grid.451056.3
Name of funders
  • Cancer Research UK
  • Wellcome Trust
  • Worldwide Cancer Research (previously AICR)
  • Breast Cancer Now (previously Breakthrough Breast Cancer)
  • National Institute for Health Research
Researcher ORCIDs
  • 0000-0001-7484-4183
  • 0000-0001-8810-950X
  • 0000-0002-0650-4002
  • 0000-0001-6035-153X